THE BLOOD FACTOR
-
Biomarin limits marketing of its FVIII gene therapy, Roctavian
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
Research projects funded in 2024
It is safe to say that research provides better quality of life and will lead, one day, inevitably to cures. This is why the Canadian...
-
Update on hemophilia gene therapy in Canada
Montreal, March 26, 2024 – Developments in gene therapy for hemophilia B have come fast and furious over the last several months. In October 2023,...
-
Update on coagulation products – current and in the pipeline
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE.